Mengis Capital Management Inc. Has $16.39 Million Stock Position in Astrazeneca Plc $AZN

Mengis Capital Management Inc. increased its holdings in Astrazeneca Plc (NYSE:AZN) by 7.5% in the 4th quarter, Holdings Channel reports. The fund owned 93,361 shares of the company’s stock after buying an additional 6,519 shares during the quarter. Astrazeneca accounts for about 2.9% of Mengis Capital Management Inc.’s investment portfolio, making the stock its 5th biggest position. Mengis Capital Management Inc.’s holdings in Astrazeneca were worth $16,385,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Brighton Jones LLC increased its stake in shares of Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares in the last quarter. Amundi grew its stake in shares of Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after buying an additional 3,618 shares during the last quarter. Jump Financial LLC grew its stake in shares of Astrazeneca by 898.4% in the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after buying an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after buying an additional 559 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Weiss Ratings reissued a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Down 0.0%

Astrazeneca stock opened at $174.87 on Friday. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The stock has a fifty day simple moving average of $186.62 and a two-hundred day simple moving average of $186.27. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market cap of $271.20 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities analysts predict that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.